Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition


Company to focus on Kv7.2/3 channel opener program and development of lead candidate, ETX-123

Visit link:
Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

Related Posts